Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Biotechnology

Adam's Take

With its silence on key questions, Omeros raises doubts about its rare disease drug

By Adam Feuerstein

In the Know

Biotech recruiter’s advice to women: You don’t have to be perfect

By Meghana Keshavan

advertisement

Politics

Who gets all that biopharma lobbying money?

By Charles Piller

advertisement

Biotech

Why it’s the timing, not the total sum, that matters most in Roivant’s big deal

By Damian Garde

Biotech

MyoKardia drug improves blood flow in patients with serious, inherited form of heart disease

By Adam Feuerstein

Biotech

We touch our phones 4,000 times a day. Can this behavior predict mental illness?

By Charles Piller

Biotech

The Shkreli saga: What’s changed? What hasn’t? And what’s next?

By Damian Garde

advertisement

Pharma

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

By Meghana Keshavan

advertisement

Adam's Take

Ziopharm claims FDA loves its brain cancer gene therapy, so why is the Phase 3 study taking so long to start?

By Adam Feuerstein

Biotech

Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline

By Damian Garde

Pharma

Pharma companies flock to new drug production approach that promises big savings

By Jonathan Wosen

Biotech

How did biotech become a Hollywood supervillain?

By Damian Garde

Pharma

These 10 drugs each rang up more than $4 billion in U.S. sales last year

Hospitals

Expanding his medical empire is good for Patrick Soon-Shiong. But is it good for patients?

By Rebecca Robbins

Pharma

How do you measure value in a drug — or anything else in medicine?

By Ike Swetlitz

Biotech

Are short sellers ruining biotech? That’s ‘hogwash,’ analysts say

By Damian Garde

STAT Live

Read the archive of STAT’s live blog as we analyzed a crucial FDA meeting on experimental CAR-T cancer treatment

By Adam Feuerstein and Damian Garde

Biotech

Forget the science. These investors think they can pick biotech winners by algorithm

By Damian Garde

Business

Gene therapy in hemophilia advances with big drops in patient bleeding rates

By Adam Feuerstein

Biotech

Experimental gene-silencing drug from Alnylam and Sanofi shows strong results in hemophilia

By Adam Feuerstein

Business

Ocular Therapeutix FDA approval imperiled by drug contamination concerns

By Adam Feuerstein

In the Lab

Personalized cancer vaccines vanquish melanoma in small but encouraging study

By Sharon Begley

Biotech

Before a biotech stock debacle, one Republican congressman made a prescient trade

By Damian Garde

Biotech

New chief aims to remake Sanofi Genzyme

By Robert Weisman

Biotech

Cara Therapeutics: A lesson in clinical trial failure and spin

By Adam Feuerstein

Health

Their children are dying. So these families are racing to raise money for research no one else will fund

By Meghana Keshavan

Exclusive

Top investor slashes Moderna’s valuation as company struggles to live up to its own hype

By Damian Garde

Politics

House Republicans backed this biotech — and lost big. Its stock is now worth 4 cents a share

By Damian Garde

Biotech

Merck shocks with CETP cholesterol study win; Ra Pharma’s scant PNH data

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT